Navigation Links
Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress
Date:7/10/2009

SOUTH SAN FRANCISCO, Calif., July 10 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced several scientific presentations at the International Society on Thrombosis and Haemostasis (ISTH) XII Congress in Boston that will feature its investigational antiplatelet drug elinogrel, a P2Y(12) ADP receptor antagonist currently in Phase II clinical development, and its oral Factor Xa inhibitor anticoagulant antidote in pre-clinical development, as well as a presentation by Portola co-founder David Phillips on new directions in antithrombotic drug discovery.

In the past six months, Portola has announced global development and commercialization agreements with Novartis for elinogrel and with Merck & Co., Inc. for betrixaban, an investigational oral Factor Xa inhibitor anticoagulant currently in Phase II clinical development.

Scientific Presentations

A Functional Pool of P2Y12 Receptors Exposed Upon Platelet Activation Persists in Mice Treated with High Dose Clopidogrel, and Can Be Blocked by Elinogrel, a Direct Acting Reversible P2Y12 Inhibitor (Presentation #PP-MO-045)

    Presenter:   Helena Haberstock-Debic
    Date: Monday, July 13, 12:30-2:15 p.m.       
    Location:  Poster Area, Platelet Biology

New Directions in Antithrombotic Drug Discovery: Pharmacological Uncoupling of Arterial thrombosis from Hemostasis (Presentation #AS-TU-026)

    Presenter: David Phillips
    Date: Tuesday, July 14, 1:15-1:45 p.m.
    Location:  Room 104 ABC, Platelets and Systemic Disorders

The Antiplatelet Effect of a New, Direct Acting, Reversible P2Y12 Inhibitor, Elinogrel (PRT060128) in Patients with High Platelet Reactivity During Clopidogrel Therapy (Presentation #PP-WE-801)

    Presenter: Paul Gurbel
    Date: Wednesday, July 15, 12:30-2:15 p.m.   
    Location:  Poster Area, Patient Oriented Studies of Antiplatelet Therapy 
     

ADP-Mediated Aggregation as a Pharmacodynamic Assay Underestimates the Antithrombotic Activity of Elinogrel, a Competitive, Reversible P2Y12 Inhibitor, Relative to Clopidogrel (Presentation #PP-TH-027)

    Presenter:  Pamela Conley
    Date: Thursday, July 16, 12:30-2:15 p.m.  
    Location:  Poster Area, Platelet Biology

Clopidogrel and Prasugrel Prolong Primary Hemostasis in the Mouse Beyond Levels Associated with P2Y12 Inhibition (Presentation #AS-TH-022)

    Presenter:  Patrick Andre
    Date: Thursday, July 16, 2:15-3:45 p.m.       
    Location:  157 ABC Oral, Platelets as Drug Targets

Reconstructed Recombinant Factor Xa as an Antidote to Reverse Anticoagulation by Factor Xa Inhibitors (Presentation #OC-TH-107)

    Presenter:  Genmin Lu
    Date: Thursday, July 16, 4:00-5:00 p.m.
    Location:  102 AB Oral, Inhibitors of Coagulation and Fibrinolysis

About Portola Pharmaceuticals, Inc.

Portola Pharmaceuticals develops innovative therapeutics based on targets with established proof of concepts that are designed to provide significant advances over current treatments for cardiovascular disease, inflammatory disease and cancer. The company has global development and commercialization agreements with two of the world's leading pharmaceutical companies collectively valued at about $1B in upfront and milestone payments plus escalating double-digit royalties on future sales. Betrixaban, its oral Factor Xa inhibitor is licensed to Merck & Co., Inc., and elinogrel, its P2Y(12) ADP receptor antagonist and potential competitor for Plavix* (clopidogrel), is licensed to Novartis. Both betrixaban and elinogrel are Phase II product candidates that have best-in-class features to address the global multi-billion hospital, specialty, and chronic care anticoagulant and antiplatelet markets, respectively.

Portola also has proprietary pipeline programs focused on the discovery and development of novel, specific Syk and JAK inhibitors to treat cancer and inflammatory diseases; a thromboxane receptor antagonist, which is an aspirin replacement product for patients intolerant to aspirin; and a novel anticoagulant antidote program with the potential to help manage or reverse the bleeding complications in the tens of millions of patients expected to be treated with anticoagulants worldwide in the next decade. For additional information, visit www.portola.com.

* Plavix(R) is a registered trademark of Sanofi/Aventis and Bristol Myers Squibb.


'/>"/>
SOURCE Portola Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Portola Pharmaceuticals to Host Conference Call at 11:00 a.m. Eastern Time Tomorrow to Discuss Betrixaban Partnership and Provide Corporate Update
2. Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel
3. Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
4. MAP Pharmaceuticals Announces Termination of Pediatric Asthma Collaboration
5. Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
6. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
7. Transdel Pharmaceuticals Completes Enrollment in Phase 3 Clinical Study for Novel Topical Pain Treatment
8. Arena Pharmaceuticals Announces Public Offering of Common Stock
9. Solvay Pharmaceuticals, Inc. Announces Commercial Availability of CREON(R) (Pancrelipase) Delayed-Release Capsules
10. Jazz Pharmaceuticals Pays Accrued Interest Under Senior Secured Notes
11. Jazz Pharmaceuticals Completes $7 Million Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... Viejo, CA (PRWEB) , ... February 18, 2017 ... ... animating paragraph presets. Use Pixel Film Studios ’ ProParagraph Fashion Volume ... descriptions, and so many other applications. Users can pick and choose from ...
(Date:2/17/2017)... ... February 17, 2017 , ... Wells Pharmacy Network offers physicians ... controlled and non-controlled substances plus the ability to manage orders on their desktop ... now accept electronic prescriptions, according to the Office of the National Coordinator of ...
(Date:2/17/2017)... ... 2017 , ... Qualis Health, one of the nation's leading ... DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that are ... award categories, highlighting four of the organization’s current programs:, , ...
(Date:2/17/2017)... ... 2017 , ... PrideStaff, a national staffing organization, is pleased ... Industry Analysts' 2017 "Staffing 100 North America" list. , Now in its ... the staffing industry over the last twelve months. Industry insiders and observers nominate ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... planning assistance to families and business owners in the greater Fort Lauderdale metropolitan ... organization. , For more than 30 years, LifeNet 4 Families has provided ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... -- Quest Diagnostics (NYSE: DGX ), the ... that it has been named one of the "World,s ... The annual survey designated Quest Diagnostics as one ... and Other Services" industry to attain Most Admired status, ... the designation. This is the second consecutive year Quest ...
(Date:2/16/2017)...  Newly published research from the CVS Health (NYSE: ... a private retailer can play in restricting access to ... today in the American Journal of Public Health ... from all CVS Pharmacy stores reduced the number of ... greater impact on those who bought cigarettes exclusively at ...
(Date:2/16/2017)... SCOTTSDALE, Ariz. , Feb. 16, 2017 /PRNewswire/ ... Exchange (HIE), announced today it is partnering with Orion Health ... contains 98% of all Maine residents, ... hospitals and over 500 ambulatory care sites. ... plans to deploy Orion Health,s Amadeus , a precision ...
Breaking Medicine Technology: